Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 12,523 matching trials from the live ClinicalTrials.gov search.

Filters: Miami, Florida Clear all

Conditions: Mental Health Wellness 1
Interventions: Jump Start Plus COVID Support, Healthy Caregivers-Healthy Children (HC2); Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 2 Years and older
Enrollment: 1,505 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Metastatic Breast Cancer
Interventions: Pertuzumab, Placebo, Trastuzumab, Docetaxel; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 159
States / cities: Scottsdale, Arizona • Jonesboro, Arkansas • Alhambra, California + 120 more

Conditions: Vascular Closure
Interventions: Not listed
Lead sponsor: Clinyx, LLC; Other
Eligibility: 18 Years and older
Enrollment: 2,517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lactose Intolerance
Interventions: RP-G28; Drug
Lead sponsor: Ritter Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetic Gastroparesis
Interventions: Metoclopramide Nasal Spray, Placebo Nasal Spray; Drug
Lead sponsor: Evoke Pharma; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 50
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 46 more

Conditions: Procedural Sedation, Endoscopy
Interventions: CNS 7056, Midazolam; Drug
Lead sponsor: Paion UK Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 7
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 4 more

Conditions: Hepatitis C, Chronic
Interventions: eltrombopag, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 59
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 49 more

Conditions: Relapsed, Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions: Betalutin; Drug
Lead sponsor: Nordic Nanovector; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: San Diego, California • San Francisco, California • Miami, Florida

Conditions: Ventral Hernia
Interventions: AGN-151607-DP, Placebo for AGN-151607-DP; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 13
States / cities: Riverside, California • Jacksonville, Florida • Miami, Florida + 10 more

Conditions: Breast Cancer
Interventions: gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 31
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 27 more

Conditions: Liver Transplant; Complications, Cirrhosis, End Stage Liver DIsease, Medication Adherence
Interventions: TEST Intervention; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Miami, Florida • Chicago, Illinois • Philadelphia, Pennsylvania

Conditions: Head and Neck Cancer
Interventions: Retifanlimab, INCAGN02385, INCAGN02390, Placebo; Drug
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 24
States / cities: Scottsdale, Arizona • Duarte, California • Irvine, California + 20 more

Conditions: Renal Insufficiency
Interventions: Epetraborole; Drug
Lead sponsor: AN2 Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Saint Paul, Minnesota

Conditions: Pneumococcal Disease
Interventions: 20vPnC; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 15 Months to 17 Years
Enrollment: 839 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 43
States / cities: Fayetteville, Arkansas • Jonesboro, Arkansas • San Diego, California + 30 more

Conditions: Cervical Cancer
Interventions: tisotumab vedotin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more

Conditions: Heart Failure, Congestive and Microalbuminuria
Interventions: metoprolol xl, carvedilol MR, lisinopril; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 72
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 60 more

Conditions: Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
Interventions: Teplizumab, Placebo infusion; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 45 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 17
States / cities: San Francisco, California • Stanford, California • Denver, Colorado + 13 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 5 more

Conditions: Spinal Cord Injury
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1991 – 2040
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Attention Deficit/Hyperactivity Disorder
Interventions: Centanafadine Hydrochloride; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 4 Years to 18 Years
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 84
States / cities: Dothan, Alabama • Saraland, Alabama • Phoenix, Arizona + 62 more

Conditions: Lung Cancer
Interventions: carboplatin, paclitaxel, thalidomide, radiation therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 235
States / cities: Fort Smith, Arkansas • Modesto, California • Salinas, California + 168 more

Conditions: Sleep Initiation and Maintenance Disorders
Interventions: Ramelteon; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 122
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 119 more

Conditions: Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions: CAT-2003, Placebo, Statin; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 13
States / cities: Muscle Shoals, Alabama • Los Angeles, California • Jacksonville, Florida + 7 more

Conditions: Rosacea
Interventions: Azelaic acid, Vehicle, Finacea; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,009 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 30
States / cities: Fremont, California • Santa Monica, California • Brandon, Florida + 26 more

Search by objective public record fields.

Jump Start Plus COVID-19 Support

A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer

Groin Complications Post Percutaneous Coronary Intervention Using Either Manual Compression or PERCLOSE Device

Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects

Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis

Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair

Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer

Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

A Trial of Tisotumab Vedotin in Cervical Cancer

COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors

Male Fertility Program

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

Efficacy of Ramelteon in Subjects With Chronic Insomnia

Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia

A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea